- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
- Others
Hepatitis Treatment Market size was valued at USD 4.2 Billion in 2022 and expected to reach USD 6.4 Billion by 2029, at a CAGR of 5.7% from 2023-2029. Hepatitis is the disease characterized by the inflammation of the liver. Hepatitis mainly occur due to the viral infections, heavy alcohol intake, consumption of hepatotoxic drugs, blood transfusions and autoimmune diseases among others. Hepatitis is classified as hepatitis A, B, C, D, E in which hepatitis A, B, C mostly occurs in humans. The symptoms associated with hepatitis include poor appetite, whites of eyes, discoloration of skin, vomiting, abdominal pain, and diarrhoea among others. Hepatitis can be prevented by the administration of vaccines in newborn babies. Increase in the incidence of different types of hepatitis infections, the rise in R&D activities for the development of newer drugs and vaccines, government initiations for the prevention of hepatitis, promising pipeline products for the hepatitis treatment are anticipated to fuel the hepatitis treatment market over the forecast period. Moreover, the rise in awareness about hepatitis treatment options among key stakeholders, increase in the consumption of alcohol, and high usage of hepatotoxic drugs and other toxins are expected to propel the hepatitis treatment market over the forecast period. However, stringent regulatory policies for the product approval, lack of vaccines for certain types hepatitis such as hepatitis C, and the high cost of the treatment are expected to hinder the growth of hepatitis treatment market over the forecast period.
Hepatitis Treatment Market Key Developments:
- For instance, in June 2016, FDA approved Epclusa manufactured by Gilead Sciences, Inc. used in the treatment of chronic hepatitis C virus infection.
- In September 2017, China Food and Drug Administration approved Gileads Sovaldi (Sofosbuvir) used in the treatment of chronic HCV infection.
- In May 2017, Eiger Biopharmaceuticals filed investigational new drug application with FDA for Lambda (pegylated interferon lambda 1a) for the treatment of hepatitis D.
Hepatitis Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
5.7%
Largest Market
North America
Fastest Growing Market
Europe
Hepatitis Treatment Market Dynamics
hepatitis treatment market is driven by rising in the prevalence of various types of hepatitis infections. According to WHO in 2015, approximately 257 Mn hepatitis B, 71 Mn hepatitis C cases, and approximately 15 Mn hepatitis D cases observed around the globe. Majority of the local and international market players are actively seeking to develop newer drugs and vaccines for the treatment of hepatitis infection. Moreover, strong product pipeline for hepatitis treatment expected to upsurge the market revenue over the forecast timeframe. Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies adopted by the market players for dominating the hepatitis treatment market.
North-America Got Significant Share
Hepatitis Treatment Market Regional Analysis
Geographically, global hepatitis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America hepatitis treatment market is poised to grow due to increase in the prevalence of hepatitis infection, the rise in R&D activities for the innovation of new drugs, an increase in healthcare expenditure in the region. Europe hepatitis treatment market expected to exhibit lucrative growth owing to rise in prevalence of hepatitis due to change in lifestyle, increase in awareness about the hepatitis treatment, and adoption of newer drugs and vaccines are propelling the market. Asia Pacific hepatitis treatment market is growing due to increase in the geriatric population in India, China, and Japan, the rise in healthcare expenditure, and launching of generic drugs into the market. Latin America hepatitis treatment market is driven by an increase in hepatitis C infection, launching of newer products into the market, and increase in the awareness about hepatitis treatment. Middle East and Africa hepatitis treatment market growth is attributed to economic growth, increase in the prevalence of hepatitis infection in African countries, and expansion of businesses by market players in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Hepatitis Treatment Market Segmentation
By Disease Type
By Drug Type
- Vaccines
- Anti-Viral Drugs
- Interferons
- Others
By Route Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Frequently Asked Questions
The hepatitis treatment market is projected to expand at a CAGR of 5.7% during the forecast period
Hoffmann- La Roche Ltd, Gilead Sciences, Novartis AG, Bristol-Myers Squibb, GlaxoSmithKline, plc.
Europe is the fastest-growing region for hepatitis treatment market
| 1.Executive Summary |
| 2.Global Hepatitis Treatment Market Introduction |
| 2.1.Global Hepatitis Treatment Market - Taxonomy |
| 2.2.Global Hepatitis Treatment Market - Definitions |
| 2.2.1.Disease Type |
| 2.2.2.Drug Type |
| 2.2.3.Route of Administration |
| 2.2.4.Distribution Channel |
| 2.2.5.Region |
| 3.Global Hepatitis Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Hepatitis Treatment Market Analysis, 2018-2022 and Forecast 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Hepatitis Treatment Market By Disease Type , 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 5.1. Hepatitis A |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Hepatitis B |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Hepatitis C |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Hepatitis D |
| 5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Hepatitis E |
| 5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6.Global Hepatitis Treatment Market By Drug Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 6.1. Vaccines |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Anti-Viral Drugs |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Interferons |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Hepatitis Treatment Market By Route of Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 7.1. Oral |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Parenteral |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8.Global Hepatitis Treatment Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 8.1. Hospital Pharmacies |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacies |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacies |
| 8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9.Global Hepatitis Treatment Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Hepatitis Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 10.1. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Hepatitis A |
| 10.1.2.Hepatitis B |
| 10.1.3.Hepatitis C |
| 10.1.4.Hepatitis D |
| 10.1.5.Hepatitis E |
| 10.1.6.Others |
| 10.2. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Vaccines |
| 10.2.2.Anti-Viral Drugs |
| 10.2.3.Interferons |
| 10.2.4.Others |
| 10.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Oral |
| 10.3.2.Parenteral |
| 10.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospital Pharmacies |
| 10.4.2.Retail Pharmacies |
| 10.4.3.Online Pharmacies |
| 10.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Hepatitis Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 11.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Hepatitis A |
| 11.1.2.Hepatitis B |
| 11.1.3.Hepatitis C |
| 11.1.4.Hepatitis D |
| 11.1.5.Hepatitis E |
| 11.1.6.Others |
| 11.2. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Vaccines |
| 11.2.2.Anti-Viral Drugs |
| 11.2.3.Interferons |
| 11.2.4.Others |
| 11.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Oral |
| 11.3.2.Parenteral |
| 11.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospital Pharmacies |
| 11.4.2.Retail Pharmacies |
| 11.4.3.Online Pharmacies |
| 11.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 11.5.7. |
| 12.Asia Pacific (APAC) Hepatitis Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 12.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Hepatitis A |
| 12.1.2.Hepatitis B |
| 12.1.3.Hepatitis C |
| 12.1.4.Hepatitis D |
| 12.1.5.Hepatitis E |
| 12.1.6.Others |
| 12.2. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Vaccines |
| 12.2.2.Anti-Viral Drugs |
| 12.2.3.Interferons |
| 12.2.4.Others |
| 12.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Oral |
| 12.3.2.Parenteral |
| 12.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospital Pharmacies |
| 12.4.2.Retail Pharmacies |
| 12.4.3.Online Pharmacies |
| 12.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Hepatitis Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 13.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Hepatitis A |
| 13.1.2.Hepatitis B |
| 13.1.3.Hepatitis C |
| 13.1.4.Hepatitis D |
| 13.1.5.Hepatitis E |
| 13.1.6.Others |
| 13.2. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Vaccines |
| 13.2.2.Anti-Viral Drugs |
| 13.2.3.Interferons |
| 13.2.4.Others |
| 13.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Oral |
| 13.3.2.Parenteral |
| 13.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospital Pharmacies |
| 13.4.2.Retail Pharmacies |
| 13.4.3.Online Pharmacies |
| 13.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Hepatitis Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 14.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Hepatitis A |
| 14.1.2.Hepatitis B |
| 14.1.3.Hepatitis C |
| 14.1.4.Hepatitis D |
| 14.1.5.Hepatitis E |
| 14.1.6.Others |
| 14.2. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Vaccines |
| 14.2.2.Anti-Viral Drugs |
| 14.2.3.Interferons |
| 14.2.4.Others |
| 14.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Oral |
| 14.3.2.Parenteral |
| 14.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospital Pharmacies |
| 14.4.2.Retail Pharmacies |
| 14.4.3.Online Pharmacies |
| 14.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Hoffmann- La Roche Ltd. (Switzerland) |
| 15.2.2.Gilead Sciences (U.S.) |
| 15.2.3.Novartis AG (Switzerland) |
| 15.2.4.Bristol-Myers Squibb (U.S) |
| 15.2.5.GlaxoSmithKline, plc. |
| 15.2.7.Merck and Co, Inc. (U.S) |
| 15.2.8.Johnson & Johnson Services, Inc. (U.S.) |
| 15.2.9.AbbVie Inc. (U.S.) |
| 15.2.10.Novira Therapeutics Inc. (U.S.) |
| 15.2.11.Eiger Biopharmaceuticals (U.S.) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Hoffmann- La Roche Ltd. (Switzerland)
- Gilead Sciences (U.S.)
- Novartis AG (Switzerland)
- Bristol-Myers Squibb (U.S)
- GlaxoSmithKline, plc.
- Merck and Co, Inc. (U.S)
- Johnson & Johnson Services, Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Novira Therapeutics Inc. (U.S.)
- Eiger Biopharmaceuticals (U.S.)